Thomas P. Johnston

Thomas P. Johnston

Auto-generated profile, based on publicly available information

Thomas P. Johnston

Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Autoimmunity Reviews
Verified
Journal Article
Closed access
AMAmir Abbas Momtazi-Borojeni
Amir Abbas Momtazi-Borojeni
SHSaeed Mohammadian Haftcheshmeh
Saeed Mohammadian Haftcheshmeh
SESeyed-Alireza Esmaeili
Seyed-Alireza Esmaeili
TJThomas P. Johnston
Thomas P. Johnston
EAElham Abdollahi
Elham Abdollahi
Amirhossein SahebkarAmirhossein Sahebkar
Amirhossein Sahebkar

1 June 2017 in Pharmacological Research
Verified
Journal Article
Closed access
TJT.P. Johnston
T.P. Johnston
Tatiana A. Alexandrovna KorolenkoTatiana A. Alexandrovna Korolenko
Tatiana A. Alexandrovna Korolenko
Matteo PirroMatteo Pirro
Matteo Pirro
Amirhossein SahebkarAmirhossein Sahebkar
Amirhossein Sahebkar

Verified
Journal Article
Open access
PDF file
AJAmin Javadifar
Amin Javadifar
SRSahar Rastgoo
Sahar Rastgoo
Maciej BanachMaciej Banach
Maciej Banach
TJTannaz Jamialahmadi
Tannaz Jamialahmadi
TJThomas P. Johnston
Thomas P. Johnston
Amirhossein SahebkarAmirhossein Sahebkar
Amirhossein Sahebkar
Atherosclerosis is a major cause of human cardiovascular disease, which is the leading cause of mortality around the world. Various physiological and pathological processes are involved, including chronic inflammation, dysregulation of lipid metabolism, development of an environment characterized by oxidative stress and improper immune responses. Accordingly, the expansion of novel targets for the treatment of atherosclerosis is necessary. In this study, we focus on the role of foam cells in the development of atherosclerosis. The specific therapeutic goals associated with each stage in the formation of foam cells and the development of atherosclerosis will be considered. Processing and metabolism of cholesterol in the macrophage is one of the main steps in foam cell formation. Cholesterol processing involves lipid uptake, cholesterol esterification and cholesterol efflux, which ultimately leads to cholesterol equilibrium in the macrophage. Recently, many preclinical studies have appeared concerning the role of non-encoding RNAs in the formation of atherosclerotic lesions. Non-encoding RNAs, especially microRNAs, are considered regulators of lipid metabolism by affecting the expression of genes involved in the uptake (e.g., CD36 and LOX1) esterification (ACAT1) and efflux (ABCA1, ABCG1) of cholesterol. They are also able to regulate inflammatory pathways, produce cytokines and mediate foam cell apoptosis. We have reviewed important preclinical evidence of their therapeutic targeting in atherosclerosis, with a special focus on foam cell formation.

1 April 2004 in Journal of Cardiovascular Pharmacology
Verified
Journal Article
Closed access
TJThomas P. Johnston
Thomas P. Johnston
We are continuing to both elucidate underlying mechanisms and identify clinical applications for a chemically induced murine model of dose-controlled hyperlipidemia and atherosclerosis. This murine model neither utilizes genetically modified mice nor a high-fat, cholate-containing diet, although simultaneous ingestion of a high-fat, cholate-enriched diet potentiates the hyperlipidemic response and the number and size of aortic atherosclerotic lesions formed in C57BL/6 mice. The chemical agent used to induce hyperlipidemia is poloxamer 407 (P-407), a nonionic surface-active-agent. To date, we have investigated the effect of P-407 on the biologic activity of a variety of key enzymes involved with lipid metabolism and transport. These enzymes include 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, lipoprotein lipase (LPL), cholesterol 7alpha-hydoxylase (C7alphaH), sterol 27-hydroxylase (S27H), lecithin cholesterol acyltransferase (LCAT), cholesteryl-ester-transfer-protein (CETP), hepatic lipase (HL), and endothelial lipase (EL). P-407 directly inhibits the heparin-releasable fraction of LPL and HL and indirectly increases the biologic activity of CETP and LCAT. Long-term (> 4 months) administration of P-407 to C57BL/6 mice appears to have no effect on the biologic activity of S27H and HMG-CoA reductase, but decreases the activity of C7alphaH. This would suggest that hypertriglyceridemia and hypercholesterolemia result from inhibition of LPL and C7alphaH, respectively, while the biologic activity of CETP and LCAT are indirectly increased to compensate for the increased cholesterol burden. The above model has proven useful for predicting the therapeutic efficacy of existing and possibly newer statin drugs, as well as evaluating the potential of one statin drug (atorvastatin calcium) to cause the regression of P-407-induced atherosclerotic lesions in mice. The P-407-induced murine model of atherogenesis represents an alternative to the use of either genetically modified or diet-induced models and may also prove beneficial for the evaluation of newer classes of antihyperlipidemic agents such as antioxidants, CETP inhibitors, and liver X receptor (LXR) agonists.

1 November 2022 in Trends in Cardiovascular Medicine
Verified
Journal Article
Closed access
AGArmita Mahdavi Gorabi
Armita Mahdavi Gorabi
NKNasim Kiaie
Nasim Kiaie
AKArezou Khosrojerdi
Arezou Khosrojerdi
TJTannaz Jamialahmadi
Tannaz Jamialahmadi
Khalid Al-RasadiKhalid Al-Rasadi
Khalid Al-Rasadi
ASAmirhossein Sahebkar
Amirhossein Sahebkar